CLRB - セレクタ・バイオサイエンシ―ズ （Cellectar Biosciences Inc.） セレクタ・バイオサイエンシ―ズCLRBのチャート
CLRBの企業情報
| symbol | CLRB |
|---|---|
| 会社名 | Cellectar Biosciences Inc （セレクタ・バイオサイエンシ―ズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 Cellectar Biosciences Inc. formerly Novelos Therapeutics Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates including radiotherapeutic and chemotherapeutic PDC''s. The Company''s PDC product portfolio includes CLR 131 which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125 which is for the treatment of micro metastatic disease; CLR 124 which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502 which is for intraoperative tumor margin illumination and non-invasive tumor imaging and CTX Product Portfolio including CLR 1601-PTX CLR 1602-PTX and CLR 1603-PTX product candidates. セレクタ・バイオサイエンシ―ズは米国のバイオ医薬品企業。癌治療薬、癌標的の投影剤の開発に従事。同社の癌注力技術は癌幹細胞を含む癌細胞に対する薬剤の選択的送達を可能にする。開発中の製品候補は、癌標的陽電子放射断層撮影造影剤I-124-CLR1404、癌標的分子放射線治療I-131-CLR1404、非放射光造影剤CLR1502など。 Cellectar Biosciences is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. The company's core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company's PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations. The company's product pipeline includes one preclinical PDC chemotherapeutic program (CLR 1900) and multiple partnered PDC assets. |
| 本社所在地 | 3301 Agriculture Drive Madison WI 53716 USA |
| 代表者氏名 | Stephen Anthony Hill スティーブン・アンソニー・ヒル |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 608-441-8120 |
| 設立年月日 | 35217 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | － |
| url | www.cellectar.com |
| nasdaq_url | https://www.nasdaq.com/symbol/clrb |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -12.53883 |
| 終値（lastsale） | 2.715 |
| 時価総額（marketcap） | 10311094.875 |
| 時価総額 | 時価総額（百万ドル） 10.21615 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 6.03918 |
| 当期純利益 | 当期純利益（百万ドル） -15.39489 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Cellectar Biosciences Inc revenues was not reported. Net loss increased 6% to $6.4M. Higher net loss reflects (Loss)/Gain on revaluation of derivative decrease from $8K (income) to $47K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$4.73 to -$3.75. |
CLRBのテクニカル分析
CLRBのニュース
Striking Stock: CTI BioPharma Corp. (NASDAQ:CTIC), Cellectar Biosciences, Inc. (NASDAQ:CLRB) 2021/11/29 03:48:48 Stock Equity
CTI BioPharma Corp. (CTIC) with the stream of 5.98% also noticed, India Cellectar Biosciences, Inc. (CLRB) encountered a rapid change of -3.61% in the last hour of trading session. CTI The post Striking Stock: CTI BioPharma Corp. (NASDAQ:CTIC), Cellectar Biosciences, Inc. (NASDAQ:CLRB) appeared first on Stocks Equity .
Vanguard Group Inc. Purchases 231,180 Shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) 2021/11/26 09:20:46 Dakota Financial News
Vanguard Group Inc. lifted its position in shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB) by 14.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,874,584 shares of the biopharmaceutical companys stock after buying an additional 231,180 shares during the quarter. Vanguard Group Inc. owned []
Up to Date Stock in Focus: Bumble Inc. (NASDAQ:BMBL), Cellectar Biosciences, Inc. (NASDAQ:CLRB) 2021/11/22 04:08:19 Stock Equity
Bumble Inc. (BMBL) with the stream of -4.19% also noticed, India Cellectar Biosciences, Inc. (CLRB) encountered a rapid change of -4.55% in the last hour of Fridays trading session. Bumble The post Up to Date Stock in Focus: Bumble Inc. (NASDAQ:BMBL), Cellectar Biosciences, Inc. (NASDAQ:CLRB) appeared first on Stocks Equity .
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Sees Significant Decrease in Short Interest 2021/11/19 18:20:42 Transcript Daily
Cellectar Biosciences, Inc. (NASDAQ:CLRB) was the target of a large drop in short interest in October. As of October 29th, there was short interest totalling 97,700 shares, a drop of 38.4% from the October 14th total of 158,700 shares. Based on an average daily trading volume, of 518,400 shares, the short-interest ratio is presently 0.2 []
Wiling stocks: Verb Technology Company, Inc. (NASDAQ:VERB 0.24%), Cellectar Biosciences, Inc. (NASDAQ:CLRB 3.12%) 2021/10/29 00:16:00 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Wiling stocks: Verb Technology Company, Inc. (NASDAQ:VERB 0.24%), Cellectar Biosciences, Inc. (NASDAQ:CLRB 3.12%) appeared first on Stocks Equity .
Cellectar Biosciences (NASDAQ:CLRB) Downgraded by Zacks Investment Research to Hold 2021/10/13 16:29:00 Stock Market Daily
Cellectar Biosciences} stock has undergone multiple analysts rating changes in the recent past. Cellectar Biosciences Downgraded by Zacks Investment Research on 10-12-21. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy. The post Cellectar Biosciences (NASDAQ:CLRB) Downgraded by Zacks Investment Research to Hold appeared first on .
Astonishing stocks: Cameco Corporation (NYSE:CCJ 7.66%), Cellectar Biosciences, Inc. (NASDAQ:CLRB 3.73%) 2021/10/12 22:44:44 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Astonishing stocks: Cameco Corporation (NYSE:CCJ 7.66%), Cellectar Biosciences, Inc. (NASDAQ:CLRB 3.73%) appeared first on Stocks Equity .
Wiggling stocks: Golden Minerals Company (AMEX:AUMN 0.84%), Cellectar Biosciences, Inc. (NASDAQ:CLRB -0.30%) 2021/10/08 04:23:36 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Wiggling stocks: Golden Minerals Company (AMEX:AUMN 0.84%), Cellectar Biosciences, Inc. (NASDAQ:CLRB -0.30%) appeared first on Stocks Equity .
Wiggling stocks: Golden Minerals Company (AMEX:AUMN 0.84%), Cellectar Biosciences, Inc. (NASDAQ:CLRB -0.30%) 2021/10/08 04:23:36 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Wiggling stocks: Golden Minerals Company (AMEX:AUMN 0.84%), Cellectar Biosciences, Inc. (NASDAQ:CLRB -0.30%) appeared first on Stocks Equity .
Preliminary Data with Iopofosine I-131 in Combination with External Beam Radiation Suggests Safety and Tolerability in Relapsed or Refractory Head and Neck Cancer 2021/09/22 12:30:00 Benzinga
FLORHAM PARK, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB ), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the completion of the part A portion of a safety and tolerability study of iopofosine I-131 (iopofosine) in combination with external beam radiation (EBRT) in relapsed or refractory head and neck cancer. This Investigator initiated study is being conducted by the University of Wisconsin as part of a prestigious Specialized Program of Research Excellence (SPORE) grant awarded by the National Cancer Institute. The University of Wisconsin clinical trial under direction of principal investigator, Dr. Justine Yang Bruce is evaluating the potential for iopofosine in combination with EBRT to reduce the total dose (Grays) and number of fractions of external beam radiation while maintaining favorable tumor response rates. The reduction in the amount or fractions (doses) of EBRT has the potential to diminish the (number and severity of) adverse events associated with EBRT.
Cellectar to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit 2021/09/15 20:01:00 Intrado Digital Media
FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that James Caruso, president and CEO, will present a company overview at the following upcoming conference:
Cellectar Receives $2M NIH Grant For Rare Lymphoma Study 2021/08/18 15:54:58 Benzinga
Cellectar Biosciences Inc (NASDAQ: CLRB ) has received a peer-reviewed National Institutes of Health (NIH) Phase II Small Business Innovation Research (SBIR) grant of approximately $2 million from the National Cancer Institute (NCI). The Company is currently conducting a pivotal study of iopofosine I-131 Full story available on Benzinga.com